Can resistance develop to Ixabepilone?

Like most chemotherapy drugs, resistance to ixabepilone may develop over long periods of time or with repeated use. The formation of drug resistance mainly involves the adaptive changes of tumor cells to the drug action mechanism, including tubulin structural mutations, enhanced activity of drug efflux pumps, and abnormal regulation of apoptosis pathways. Ixabepilone has certain advantages in overcoming multidrug resistance (MDR) because it can partially bypass P-glycoprotein-mediated drug efflux, but it still cannot completely avoid the risk of resistance. In clinical practice, after continuous use or combined treatment with other chemotherapy drugs, some patients' tumors may experience a decrease in drug sensitivity, resulting in a weakened efficacy.

The development of drug resistance may also be related to the tumor microenvironment. For example, changes in the tumor stroma, angiogenesis, and the immune microenvironment will affect the effectiveness of the drug. Regarding the resistance mechanism of ixabepilone, researchers are exploring the combination of targeted drugs or immunotherapy to delay or reverse the resistance phenomenon. For example, some clinical studies have attempted to combine ixabepilone with anti-angiogenic drugs or immune checkpoint inhibitors to enhance anti-tumor activity and extend the duration of treatment. In addition, through genetic testing and molecular analysis, it can be predicted that some patients may be resistant to ixabepilone, so that the regimen can be optimized before treatment and the efficacy can be improved.

In actual clinical practice, doctors usually adjust the dose of ixabepilone or consider alternatives based on the patient's efficacy response, changes in tumor burden, and dynamic monitoring of biomarkers to manage the risk of resistance. This dynamic management strategy is an important means to prolong drug effectiveness and improve patients' quality of life. Although drug resistance is a problem that cannot be ignored, ixabepilone still provides a valuable option for the treatment of advanced breast cancer, especially for patients who are resistant to or relapsed with conventional chemotherapy drugs.

Reference materials:https://www.drugs.com/mtm/ixabepilone.html